Pharma working capital feels the weight of GLP-1 boom
New data from The Hackett Group found pharma's cash conversion cycle climbed to nearly 186 days in 2025 as firms increased investment in biologics and GLP-1s.
New data from The Hackett Group found pharma's cash conversion cycle climbed to nearly 186 days in 2025 as firms increased investment in biologics and GLP-1s.
BELLINGS Intelligence Score: 22
Why it matters
The rise in pharma working capital tied to the GLP-1 boom reflects a notable shift in industry operating metrics but remains a sector-specific development without immediate broad market or regulatory impact.
Sources
CFO.com
Pharma working capital feels the weight of GLP-1 boom
New data from The Hackett Group found pharma's cash conversion cycle climbed to nearly 186 days in 2025 as firms increased investment in biologics and GLP-1s.